Latest Ratios: P/E Ratio -3.9x · EV/EBITDA N/A · ROE -112.8%. (2002–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $22M | $50M | $7M | $5M | $20M | $85M | $101M | $76M | $428M | $427M | $422M |
| Enterprise Value | $25M | $52M | $9M | $7M | $22M | $82M | $102M | $81M | $428M | $428M | $422M |
| P/E Ratio → | -3.92 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 13.52 | 32.99 | 20.41 | 238.71 | 208.16 | 108.97 | 61483.61 | — | — |
| P/B Ratio | 2.68 | 3.73 | 9.51 | 4.01 | 4.31 | 9.57 | 17.27 | — | — | 173.40 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 18.11 | 46.45 | 22.49 | 231.71 | 211.82 | 115.29 | 61592.86 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 99.9% | -98.1% | 70.5% | 98.6% | 96.1% | 97.1% | -3190.5% | — | — |
| Operating Margin | — | — | -923.3% | -4439.2% | -1558.5% | -3290.1% | -1760.9% | -492.9% | -40031.1% | — | — |
| Net Profit Margin | — | — | -962.1% | -5109.3% | -1693.5% | -3608.5% | -2027.0% | -519.0% | -80152.1% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -112.8% | -112.8% | -495.9% | -266.5% | -244.0% | -174.8% | -343.7% | — | — | -172.5% | — |
| ROA | -55.3% | -55.3% | -64.0% | -83.2% | -133.3% | -90.2% | -90.3% | -103.7% | -166.4% | -128.1% | -25342.1% |
| ROIC | -56.0% | -56.0% | -110.8% | -102.3% | -174.5% | -125.7% | -107.2% | -60.2% | — | -90.5% | — |
| ROCE | -90.1% | -90.1% | -353.1% | -191.3% | -196.3% | -117.5% | -169.5% | -3044.2% | — | -164.5% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.26 | 0.26 | 4.43 | 2.21 | 0.74 | 0.38 | 1.16 | — | — | 0.50 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.21 | 3.23 | 1.64 | 0.44 | -0.28 | 0.30 | — | — | 0.39 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -19.08 | -19.08 | -5.50 | -5.11 | -51.78 | -48.34 | -25.70 | -7.32 | -12.89 | -40.00 | -1081.29 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.41 | 0.41 | 0.33 | 0.27 | 0.54 | 2.07 | 1.27 | 0.13 | 0.02 | 0.19 | 0.00 |
| Quick Ratio | 0.41 | 0.41 | 0.33 | 0.27 | 0.54 | 2.07 | 1.27 | 0.20 | 0.02 | 0.14 | 0.00 |
| Cash Ratio | 0.12 | 0.12 | 0.14 | 0.13 | 0.26 | 1.61 | 1.03 | 0.02 | 0.01 | 0.06 | 0.00 |
| Asset Turnover | — | — | 0.07 | 0.02 | 0.09 | 0.03 | 0.03 | 0.10 | 0.07 | — | — |
| Inventory Turnover | — | — | — | — | — | 0.20 | — | — | 173.66 | — | — |
| Days Sales Outstanding | — | — | 827.32 | 1818.81 | 515.44 | 437.11 | 755.17 | 333.17 | 768.15 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $23M | $12M | $4M | $3M | $3M | $2M | $2M | $1M | $1M | $1M |
Imminent liquidity and dilution
As reported in recent financial statements, ABVC's P/B ratio of 2.68 suggests that the market is pricing the firm at a significant premium to its book value, despite the company's lack of revenue and the precarious state of its cash reserves relative to its clinical development needs.
The negative P/E of -3.92 is typical for a pre-revenue biotech, yet the valuation appears to be driven more by speculative interest in the pipeline than by fundamental asset backing. Investors should monitor whether this premium holds as the company approaches a likely dilutive financing event to address its liquidity shortfall.
Based on the reported figures, ABVC's ROIC has consistently trended in negative territory, reaching -7.5% in 2026Q1, which underscores the company's inability to generate productive returns on the capital deployed into its extensive and multi-program clinical development pipeline during this early-stage phase.
The persistent decay in ROIC suggests that the company's strategy of running multiple concurrent trials is failing to create value for shareholders. This trend warrants further investigation into whether management can streamline its R&D focus to improve capital efficiency before the current cash runway is fully exhausted.
According to the 2026Q1 balance sheet, the company's current ratio has deteriorated to a critical 0.12, indicating that current liabilities significantly exceed liquid assets and leaving the firm with virtually no buffer to manage unexpected clinical trial costs or general corporate obligations in the near term.
This liquidity position appears highly vulnerable, suggesting that the company may be unable to meet its short-term obligations without immediate external capital. Investors should monitor the firm's ability to secure non-dilutive funding or licensing milestones, as the current cash position provides minimal room for operational error.
As evidenced by the company's financial disclosures, the P/B ratio is the most commonly misapplied metric for ABVC, as it obscures the fact that the firm's book value is heavily comprised of intangible assets and clinical trial costs that may hold little liquidation value in a distress scenario.
Analysts should instead focus on the cash runway and the burn rate, as these metrics provide a more accurate assessment of the company's survival probability. Relying on P/B ignores the reality that the firm's primary assets are speculative clinical candidates that require significant additional capital to reach commercialization.
Includes 30+ ratios · 24 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ABVC stock.
ABVC BioPharma, Inc.'s current P/E ratio is -3.9x. This places it at the 50th percentile of its historical range.
ABVC BioPharma, Inc.'s return on equity (ROE) is -112.8%. The historical average is -213.7%.
Based on historical data, ABVC BioPharma, Inc. is trading at a P/E of -3.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.